Wechselwirkungen · Prevymis
PREVYMIS 20 mg granules in sachet PREVYMIS 120 mg granules in sachet · Abschnitt 4.5 · PDF-Seite 74
HOS-139932 · Präparat HOS-098408
Medicinal products metabolised by CYP2B6, UGT1A1 or transported by BCRP or OATP2B1 Letermovir is a general inducer in vivo but has also been observed to inhibit CYP2B6, UGT1A1, BCRP, and OATP2B1 in vitro. The net effect in vivo is unknown. Therefore, the plasma concentrations of medicinal products that are substrates of these enzymes or transporters may increase or decrease when co-administered with letermovir. Additional monitoring may be recommended; refer to the prescribing information for such medicinal products. - Examples of medicinal products that are metabolised by CYP2B6 include bupropion. - Examples of medicinal products metabolised by UGT1A1 are raltegravir and dolutegravir. - Examples of medicinal products transported by BCRP include rosuvastatin and sulfasalazine. - An example of a medicinal product transported by OATP2B1 is celiprolol.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): bupropion (HOS-086329) sulfasalazine (HOS-089673) celiprolol (HOS-139796) dolutegravir (HOS-089992) rosuvastatin (HOS-086307) raltegravir (HOS-086187)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-12T02:00:00Z · SHA-256 db4998a6cb590006789107af9f09c4196d815ed441a57d076042c2223b8d34a9 · Passage 7b36ebe5215851576511c9391e13a703abd6367cdc0ba12114699ad98dc3e9f9 · Zeichen 8695–9556 im Abschnitt